Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

• Status: Terminated
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Patrick Northup, MD
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

• Hospitalized patients with acute or chronic liver disease

• Type I HRS

• Aged greater than or equal to 18

• Non-pregnant

Exclusion Criteria:

• Allergy or hypersensitivity to PTX or intolerance to methylxanthines (e.g. caffeine, theophylline)

• Concurrent use of nephrotoxic drugs

• Age less than 18

• Pregnancy

• Uncontrolled bacterial infection

• Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease, interstitial nephritis and urinary obstruction)

• Shock

• TNF alpha antagonist use

• Subject is institutionalized or a prisoner

• Recent cerebral or retinal hemorrhage (contraindication to PTX)

• Severe or poorly controlled cardiovascular disease as determined by the principal investigator to hinder the ability to adhere to study protocols